Yukkitoshi Takahashi

Dr. Yukkitoshi Takahashi


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2008 in Pharmacogenomics
Verified
Journal Article
Closed access
NKNahoko Kaniwa
Nahoko Kaniwa
YSYoshiro Saito
Yoshiro Saito
MAMichiko Aihara
Michiko Aihara
KMKayoko Matsunaga
Kayoko Matsunaga
MTMasahiro Tohkin
Masahiro Tohkin
RHRyuichi Hasegawa
Ryuichi Hasegawa
Introduction: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Recently, strong associations of HLA-B*1502 and HLA-B*5801 with carbamazepine- and allopurinol-induced severe cutaneous adverse reactions were found in Han Chinese patients, respectively, but ethnic differences in the associations have been reported. The objective of this study is to clarify the involvement of HLA-B*1502 and HLA-B*5801 in Japanese SJS/TEN patients. Methods: HLA-B genotyping was performed on 58 Japanese SJS/TEN patients between July 2006 and April 2008 from multicenters in Japan. Results: There were no HLA-B*1502 carriers among 58 SJS/TEN patients. This patient group included seven carbamazepine-related and 11 aromatic anti-epileptic agent-related SJS/TEN patients. In addition, there were five HLA-B*5801 carriers, which included four allopurinol-related SJS/TEN patients. Conclusion: While HLA-B*1502 is unlikely to be associated with carbamazepi...

6 August 2014 in JAMA
Verified
Journal Article
Open access
PDF file
WCWenHung Chung
WenHung Chung
WCWan-Chun Chang
Wan-Chun Chang
YLYun-Shien Lee
Yun-Shien Lee
YWYing-Ying Wu
Ying-Ying Wu
CYChih-Hsun Yang
Chih-Hsun Yang
TCthe Japan Pharmacogenomics Data Science Consortium
the Japan Pharmacogenomics Data Science Consortium
Phenytoin (diphenylhydantoin) is a widely prescribed antiepileptic drug and remains the most frequently used first-line antiepileptic drug in hospitalized patients.1,2 Although effective for treating neurological diseases, phenytoin can cause cutaneous adverse reactions ranging from mild rash (maculopapular exanthema) to life-threatening severe cutaneous adverse reactions.3-6 Phenytoin-related severe cutaneous adverse reactions include drug reactions with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).4-6 Stevens-Johnson syndrome and TEN are variants of the same mucocutaneous blistering reaction disease and carry high morbidity and mortality (10%-50%).4-6 DRESS, also known as drug-induced hypersensitivity syndrome, is characterized by generalized maculopapular eruptions, high fever, eosinophilia, atypical lymphocytes, and visceral involvement and has a mortality rate of approximately 10%.6,7 Phenytoin-related severe cutaneous adverse reactions frequently impair the internal organs, leading to the highest mortality among the different antiepileptic drug–related cutaneous reactions.5

1 March 2003 in Brain
Verified
Journal Article
Open access
PDF file
TFTateki Fujiwara
Tateki Fujiwara
TSTakashi Sugawara
Takashi Sugawara
EMEmi Mazaki‐Miyazaki
Emi Mazaki‐Miyazaki
YTYukkitoshi Takahashi
Yukkitoshi Takahashi
KFKatsuyuki Fukushima
Katsuyuki Fukushima
YIYushi Inoue
Yushi Inoue
A group of infant onset epilepsies manifest very frequent generalized tonic–clonic seizures (GTC) intractable to medical therapy, which may or may not be accompanied by minor seizures such as myoclonic seizures, absences and partial seizures. They include severe myoclonic epilepsy in infancy (SMEI) and intractable childhood epilepsy with GTC (ICEGTC). They are commonly associated with fever‐sensitivity, family history of seizure disorders and developmental decline after seizure onset. Mutations of the neuronal voltage‐gated sodium channel α subunit type 1 gene (SCN1A) were recently reported in SMEI patients. To clarify the genotypic differences in this group of epilepsies, we searched for SCN1A abnormalities in 25 patients with SMEI and 10 with ICEGTC, together with the family members of 15 patients. Frameshift mutations in SCN1A were observed in four patients, nonsense mutations in five patients, missense mutations in 21 patients, other mutations in two patients and no mutation in five patients. SMEI patients showed nonsense mutations, frameshifts, or missense mutations, while ICEGTC patients showed only missense mutations. Study of both parents of 11 patients revealed that the mutations in these patients were de novo. However, two mothers had the same missense mutations as their ICEGTC children, and they had generalized epilepsy with febrile seizures plus. Here we suggest that SMEI and ICEGTC represent a continuum with minor phenotypic and genotypic differences.

5 January 2017 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
OIon behalf of TOSCA consortium and TOSCA investigators
on behalf of TOSCA consortium and TOSCA investigators
JKJohn C. Kingswood
John C. Kingswood
GDGuillaume B. D’augères
Guillaume B. D’augères
EBElena Belousova
Elena Belousova
JFJosé C. Ferreira
José C. Ferreira
AJAnna C. Jansen
Anna C. Jansen
Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder. Many gaps remain in the understanding of TSC because of the complexity in clinical presentation. The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international disease registry designed to address knowledge gaps in the natural history and management of TSC. Here, we present the baseline data of TOSCA cohort. Patients of any age diagnosed with TSC, having a documented visit for TSC within the preceding 12 months, or newly diagnosed individuals were included. The registry includes a “core” section designed to record detailed background information on each patient including disease manifestations, interventions, and outcomes collected at baseline and updated annually. “Subsections” of the registry recorded additional data related to specific features of TSC. Baseline “core” data from 2093 patients enrolled from 170 sites across 31 countries were available at the cut-off date September 30, 2014. Median age of patients at enrollment was 13 years (range, 0–71) and at diagnosis of TSC was 1 year (range, 0–69). The occurrence rates of major manifestations of TSC included – cortical tubers (82.2%), subependymal nodules (78.2%), subependymal giant cell astrocytomas (24.4%), renal angiomyolipomas (47.2%), lymphangioleiomyomatosis (6.9%), cardiac rhabdomyomas (34.3%), facial angiofibromas (57.3%), forehead plaque (14.1%), ≥ 3 hypomelanotic macules (66.8%), and shagreen patches (27.4%). Epilepsy was reported in 1748 (83.5%) patients, of which 1372 were diagnosed at ≤ 2 years (78%). Intellectual disability was identified in 451 (54.9%) patients of those assessed. TSC-associated neuropsychiatric disorders (TAND) were diagnosed late, and not evaluated in 30–50% of patients. TOSCA is the largest clinical case series of TSC to date. It provided a detailed description of the disease trajectory with increased awareness of various TSC manifestations. The rates of different features of TSC reported here reflect the age range and referral patterns of clinics contributing patients to the cohort. Documentation of TAND and LAM was poor. A widespread adoption of the international TSC assessment and treatment guidelines, including use of the TAND Checklist, could improve surveillance. The registry provides valuable insights into the necessity for monitoring, timing, and indications for the treatment of TSC.

15 November 2018 in Epilepsia Open
Verified
Journal Article
Open access
PDF file
RNRima Nabbout
Rima Nabbout
EBElena Belousova
Elena Belousova
MBMirjana P. Benedik
Mirjana P. Benedik
TCTom Carter
Tom Carter
VCVincent Cottin
Vincent Cottin
LDLisa D′Amato
Lisa D′Amato
Summary: Objective: To present the baseline data of the international TuberOus SClerosis registry to increase disease Awareness (TOSCA) with emphasis on the characteristics of epilepsies associated with tuberous sclerosis complex (TSC).Methods: Retrospective and prospective patients’ data on all aspects of TSC were collected from multiple countries worldwide. Epilepsy variables included seizure type, age at onset, type of treatment, and treatment outcomes and association with genotype, seizures control, and intellectual disability. As for noninterventional registries, the study protocol did not specify any particular clinical instruments, laboratory investigations, or intervention. Evaluations included those required for diagnosis and management following local best practice.Results: Epilepsy was reported in 83.6% of patients (1852/2216) at baseline; 38.9% presented with infantile spasms and 67.5% with focal seizures. The mean age at diagnosis of infantile spasms was 0.4 year (median <1 year; range <1‐30 years) and at diagnosis of focal seizures was 2.7 years (median 1 year; range <1‐66 years). A total of 1469 patients (79.3%) were diagnosed with epilepsy <2 years. The rate of infantile spasms was higher in patients with a TSC2 mutation than in patients with a TSC1 mutation (47.3% vs 23%). ɣ‐aminobutyric acid (GABA)ergic drugs were the most common treatment modality for both infantile spasms (78.7%) and focal seizures (65.5%). Infantile spasms and focal seizures were controlled in 76.3% and 58.2% of patients, respectively. Control of seizures was associated with lower rates of intellectual disability in both groups.Significance: This registry reports the largest international cohort of patients with TSC. Findings confirmed the typical onset pattern of infantile spasms and other focal seizures in the first 2 years of life, and the high rates of infantile spasms in patients with TSC2 mutation. Our results underscored the occurrence of focal seizures at all ages, including an onset that preceded emergence of infantile spasms. Seizure control was shown to be associated with lower rates of intellectual disability but did not preclude the presence of intellectual disability.

3 November 2010 in Epilepsia
Verified
Journal Article
Open access
PDF file
NKNahoko Kaniwa
Nahoko Kaniwa
YSYoshiro Saito
Yoshiro Saito
MAMichiko Aihara
Michiko Aihara
KMKayoko Matsunaga
Kayoko Matsunaga
MTMasahiro Tohkin
Masahiro Tohkin
FGfor the JSAR research group
for the JSAR research group
Summary: Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life‐threatening severe cutaneous adverse reactions. Recently, strong associations of HLA‐B*1502 with carbamazepine‐induced SJS/TEN have been found in Han Chinese patients. These associations have been confirmed in several Asian populations, excluding Japanese. SJS patients carrying HLA‐B*1508, HLA‐B*1511, or HLA‐B*1521, which are members of the HLA‐B75 type along with HLA‐B*1502, were detected in studies in India and Thailand. In the current study, we genotyped the HLA‐B locus from 14 Japanese typical and atypical SJS/TEN patients in whom carbamazepine was considered to be involved in the onset of adverse reactions. Although there were no HLA‐B*1502 carriers, four patients had HLA‐B*1511. Our data suggest that HLA‐B*1511, a member of HLA‐B75, is a risk factor for carbamazepine‐induced SJS/TEN in Japanese.